Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market

Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market

Summary

GBI Research, a leading business intelligence provider, has released its latest research, “Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market”. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global antihypertensive market. The report analyzes the markets for antihypertensive disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes:
- Annualized market data for the antihypertensive disorders market from 2002 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including hypertension and PAH.
- Analysis of the antihypertensive disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the antihypertensive disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Novartis, Merck, AstraZeneca, United Therapeutics, Actelion and Pfizer.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global antihypertensive disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps. SHOW LESS READ MORE >

1 3
1.1 List of Tables 5
1.2 List of Figures 7
2 Global Anti-Hypertensives Market: Introduction 9
2.1 GBI Research Report Guidance 10
3 Global Anti-Hypertensives Market: Market Overview 11
3.1 Introduction 11
3.2 Revenue Forecasts for the Global Anti-Hypertensive Market 12
3.2.1 Sales Value 12
3.2.2 Annual Cost of Therapy 13
3.2.3 Treatment Usage Patterns 14
3.2.4 Treatment-Seeking Population 16
3.2.5 Diagnosed Population 17
3.2.6 Prescription Population 18
3.3 Anti-Hypertension Disorders Market Drivers 19
3.3.1 Steady Increase in the Hypertension and Pulmonary Arterial Hypertension Prevalence Population 19
3.3.2 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and PAH 19
3.3.3 Patent Expiries of Branded Drugs and Entry of Generics will Reduce the Annual Cost of Therapy with Anti-Hypertensives 19
3.4 Anti-Hypertension Disorders Market Restraints 20
3.4.1 Low Compliance in Hypertensive Patients 20
3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues 20
3.4.3 Low Treatment Seeking Behavior and Diagnosis in PAH 20
3.5 Generics Share in the Global Anti-Hypertension Market 21
4 Global Anti-Hypertensives Market: Therapeutic Landscape 22
4.1 Hypertension 22
4.1.1 Introduction 22
4.1.2 Sales Value 22
4.1.3 Annual Cost of Therapy 25
4.1.4 Treatment Usage Patterns 26
4.1.5 Market Share by Geography 30
4.2 Pulmonary Arterial Hypertension (PAH) Market 33
4.2.1 Introduction 33
4.2.2 Sales Value 35
4.2.3 Annual Cost of Therapy 36
4.2.4 Treatment Usage Patterns 37
4.2.5 Market Share by Geography 41
5 Global Anti-Hypertensives Market: Geographical Landscape 44
5.1 Geographical Break-up 44
5.2 The US 47
5.2.1 Sales Value 47
5.2.2 Annual Cost of Therapy 48
5.2.3 Treatment Usage Patterns 49
5.2.4 Treatment-Seeking Population 50
5.3 Top Five Countries in Europe 53
5.3.1 Sales Value 53
5.3.2 Annual Cost of Therapy 54
5.3.3 Treatment Usage Patterns 55
5.4 Japan 59
5.4.1 Sales Value 59
5.4.2 Annual Cost of Therapy 60
5.4.3 Treatment Usage Patterns 61
6 Global Anti-Hypertensives Market: Pipeline Analysis 65
6.1 Introduction 65
6.1.1 Research and Development Pipeline – Hypertension 66
6.1.2 Research and Development Pipeline – Pulmonary Arterial Hypertension 72
6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market 76
6.2.1 SPP635 76
6.2.2 Pioglitazone 77
6.2.3 LCZ696 78
6.2.4 QT1571 (imatinib) 78
6.2.5 Selexipag (NS-304, ACT-293987) 79
6.2.6 PS-433540 (DARA) 80
6.2.7 Macitentan (ACT-064992, Actelion 1) 80
6.2.8 Riociguat (BAY63-2521) 81
7 Global Anti-Hypertensives Market: Competitive Landscape 83
7.1 Market Share Analysis: Hypertension Disorders 83
7.2 Competitive Profiling 84
7.2.1 Novartis 84
7.2.2 Merck 85
7.2.3 AstraZeneca 86
7.2.4 United Therapeutics 87
7.2.5 Actelion 89
7.2.6 Pfizer 90
8 Global Anti-Hypertensives Market: Strategic Consolidations 92
8.1 Overview 92
8.2 Deals by Type 93
8.2.1 Eli Lilly Acquires ICOS in January 2007 93
8.2.2 Abbott Laboratories Acquires Solvay Pharmaceuticals in February 2010 93
8.2.3 Endo Pharmaceuticals to Acquire Qualitest Pharmaceuticals in 2010 94
8.2.4 Jubilant Organosys Acquires Trinity Laboratories and Trigen Laboratories in March 2007 94
8.3 R&D Licensing Agreements 94
8.3.1 Deals by Indication 94
8.3.2 Deals by Phase 95
8.3.3 Deals by Geography 95
8.3.4 Phase II 96
8.3.5 Approved 97
9 Global Anti-Hypertensives Market: Appendix 99
9.1 Market Definitions 99
9.2 Abbreviations 99
9.3 Research Methodology 101
9.3.1 Coverage 101
9.3.2 Secondary Research 101
9.3.3 Primary Research 101
9.3.4 Expert Panel Validation 102
9.4 Contact Us 102
9.5 Disclaimer 102
9.6 Sources 103

1.1 List of Tables
Table 1: Anti-Hypertensive Market, Global, Sales Value ($bn), 2002–2009 12
Table 2: Anti-Hypertensive Market, Global, Sales Value ($bn), 2009–2016 12
Table 3: Anti-Hypertensive Market, Global, Annual Cost of Therapy ($), 2002–2009 13
Table 4: Anti-Hypertensive Market, Global, Annual Cost of Therapy ($), 2009–2016 13
Table 5: Anti-Hypertensive Market, Global, Treatment Usage Patterns (millions), 2002–2009 15
Table 6: Anti-Hypertensive Market, Global, Treatment Usage Patterns (millions), 2009–2016 15
Table 7: Anti-Hypertensive Market, Global, Hypertension Sales Value ($bn), 2002–2009 23
Table 8: Anti-Hypertensive Market, Global, Hypertension Sales Value ($bn), 2009–2016 24
Table 9: Anti-Hypertensive Market, Global, Hypertension Annual Cost of Therapy ($), 2002–2009 25
Table 10: Anti-Hypertensive Market, Global, Hypertension Annual Cost of Therapy ($), 2009–2016 26
Table 11: Anti-Hypertensive Market, Global, Hypertension Treatment Usage Patterns (millions), 2002–2009 26
Table 12: Anti-Hypertensive Market, Global, Hypertension Treatment Usage Patterns (millions), 2009–2016 27
Table 13: Anti-Hypertensive Market, Global, Hypertension Market Geographical Segmentation ($bn), 2002–2009 31
Table 14: Anti-Hypertensive Market, Global, Hypertension Market Geographical Segmentation ($bn), 2009–2016 32
Table 15: Anti-Hypertensive Market, Global, PAH Sales Value ($bn), 2002–2009 35
Table 16: Anti-Hypertensive Market, Global, PAH Sales Value ($bn), 2009–2016 35
Table 17: Anti-Hypertensive Market, Global, PAH Annual Cost of Therapy ($), 2002–2009 36
Table 18: Anti-Hypertensive Market, Global, PAH Annual Cost of Therapy ($), 2009–2016 36
Table 19: Anti-Hypertensive Market, Global, PAH Treatment Usage Patterns (thousands), 2002–2009 37
Table 20: Anti-Hypertensive Market, Global, PAH Treatment Usage Patterns (thousands), 2009–2016 37
Table 21: Anti-Hypertensive Market, Global, PAH Market Geographical Segmentation ($m), 2002–2009 42
Table 22: Anti-Hypertensive Market, Global, PAH Market Geographical Segmentation ($m), 2009–2016 42
Table 23: Anti-Hypertensive Market, Global, Sales Value by Geography ($bn), 2002–2009 45
Table 24: Anti-Hypertensive Market, Global, Sales Value by Geography ($bn), 2009–2016 45
Table 25: Anti-Hypertensive Market, the US, Sales Value ($bn), 2002–2009 47
Table 26: Anti-Hypertensive Market, the US, Sales Value ($bn), 2009–2016 47
Table 27: Anti-Hypertensive Market, the US, Annual Cost of Therapy ($), 2002–2009 48
Table 28: Anti-Hypertensive Market, the US, Annual Cost of Therapy ($), 2009–2016 48
Table 29: Anti-Hypertensive Market, the US, Treatment Usage Patterns (millions), 2002–2009 49
Table 30: Anti-Hypertensive Market, the US, Treatment Usage Patterns (millions), 2009–2016 50
Table 31: Anti-Hypertensive Market, Top Five Countries in Europe, Sales Value ($bn), 2002–2009 53
Table 32: Anti-Hypertensive Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016 53
Table 33: Anti-Hypertensive Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2009 54
Table 34: Anti-Hypertensive Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 55
Table 35: Anti-Hypertensive Market, Top Five Countries in Europe, Treatment Usage Pattern (millions), 2002–2009 55
Table 36: Anti-Hypertensive Market, Top Five Countries in Europe, Treatment Usage Pattern (millions), 2009–2016 55
Table 37: Anti-Hypertensive Market, Japan, Sales Value ($bn), 2002–2016 59
Table 38: Anti-Hypertensive Market, Japan, Sales Value ($bn), 2009–2016 59
Table 39: Anti-Hypertensive Market, Japan, Annual Cost of Therapy ($), 2002–2009 60
Table 40: Anti-Hypertensive Market, Japan, Annual Cost of Therapy ($), 2009–2016 60
Table 41: Anti-Hypertensive Market, Japan, Treatment Usage Pattern (millions), 2002–2009 61
Table 42: Anti-Hypertensive Market, Japan, Treatment Usage Pattern (millions), 2009–2016 61
Table 43: Anti-Hypertensive Market, Global, R&D Pipeline by Phase in Hypertension Market, October 2010 67
Table 44: Anti-Hypertensive Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market, 2010 72
Table 45: Anti-Hypertensive Market, Global, Major M&A Deals, 2005-2010 93
Table 46: Anti-Hypertensive Market, Global, Licensing Agreements for Drugs in Phase II Stage, 2005–2010 96
Table 47: Anti-Hypertensive Market, Global, Licensing Agreements for Approved Drugs, 2005–2009 97

1.2 List of Figures
Figure 1: Anti-Hypertensive Market, Global, Drivers and Restraints, 2010 11
Figure 2: Anti-Hypertensive Market, Global, Sales Value ($bn), 2002–2016 12
Figure 3: Anti-Hypertensive Market, Global, Annual Cost of Therapy ($), 2002–2016 13
Figure 4: Anti-Hypertensive Market, Global, Therapeutic Usage Patterns (millions), 2002– 2016 14
Figure 5: Anti-Hypertensive Market, Global, Therapeutic Usage Patterns (millions), 2002–2016 15
Figure 6: Anti-Hypertensive Market, Global, Treatment-Seeking Population (millions), 2002–2016 16
Figure 7: Anti-Hypertensive Market, Global, Diagnosis Population (millions), 2002–2016 17
Figure 8: Anti-Hypertensive Market, Global, Prescription Population (millions), 2002–2016 18
Figure 9: Anti-Hypertensive Market, Global, Branded v/s Generic Drugs, 2010 21
Figure 10: Anti-Hypertensive Market, Global, Hypertension Sales Value ($bn), 2002–2016 23
Figure 11: Anti-Hypertensive Market, Global, Hypertension Annual Cost of Therapy ($), 2002–2016 25
Figure 12: Anti-Hypertensive Market, Global, Hypertension Treatment Usage Patterns (millions), 2002–2016 26
Figure 13: Anti-Hypertensive Market, Global, Hypertension Treatment-Seeking Population (millions), 2002–2016 27
Figure 14: Anti-Hypertensive Market, Global, Hypertension Diagnosis Population (millions), 2002–2016 28
Figure 15: Anti-Hypertensive Market, Global, Hypertension Prescription Population (millions), 2002–2016 29
Figure 16: Anti-Hypertensive Market, Global, Hypertension Market Segmentation by Geography (%), 2009 and 2016 30
Figure 17: Anti-Hypertensive Market, Global, Hypertension Market Geographical Segmentation ($bn), 2002–2016 31
Figure 18: Anti-Hypertensive Market, Global, Hypertension Market, Geography Benchmarking, 2009 32
Figure 19: Anti-Hypertensive Market, Global, PAH Sales Value ($bn), 2002–2016 35
Figure 20: Anti-Hypertensive Market, Global, PAH Annual Cost of Therapy ($), 2002–2016 36
Figure 21: Anti-Hypertensive Market, Global, PAH Treatment Usage Patterns (thousands), 2002–2016 37
Figure 22: Anti-Hypertensive Market, Global, PAH Treatment-Seeking Population (thousands), 2002–2016 38
Figure 23: Anti-Hypertensive Market, Global, PAH Diagnosis Population (thousands), 2002–2016 39
Figure 24: Anti-Hypertensive Market, Global, PAH Prescription Population (thousands), 2002–2016 40
Figure 25: Anti-Hypertensive Market, Global, PAH Market Segmentation by Geography (%), 2009 and 2016 41
Figure 26: Anti-Hypertensive Market, Global, PAH Market Geographical Segmentation ($bn), 2002–2016 42
Figure 27: Anti-Hypertensive Market, Global, PAH Market, Geography Benchmarking, 2009 43
Figure 28: Anti-Hypertensive Market, Global, Market Share by Geography (%), 2009 and 2016 44
Figure 29: Anti-Hypertensive Market, Global, Sales Value by Geography ($bn), 2002–2016 45
Figure 30: Anti-Hypertensive Market, Global, Geography Benchmarking, 2009 and 2016 46
Figure 31: Anti-Hypertensive Market, the US, Sales Value ($bn), 2002–2016 47
Figure 32: Anti-Hypertensive Market, the US, Annual Cost of Therapy ($), 2002–2016 48
Figure 33: Anti-Hypertensive Market, the US, Treatment Usage Patterns (millions), 2002–2016 49
Figure 34: Anti-Hypertensive Market, the US, Treatment-Seeking Population (millions), 2002–2016 50
Figure 35: Anti-Hypertensive Market, the US, Diagnosis Population (millions), 2002–2016 51
Figure 36: Anti-Hypertensive Market, the US, Prescription Population (millions), 2002–2016 52
Figure 37: Anti-Hypertensive Market, Top Five Countries in Europe, Sales Value ($bn), 2002–2016 53
Figure 38: Anti-Hypertensive Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2016 54
Figure 39: Anti-Hypertensive Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2016 55
Figure 40: Anti-Hypertensive Market, Top Five Countries in Europe, Treatment-Seeking Population (millions), 2002–2016 56
Figure 41: Anti-Hypertensive Market, Top Five Countries in Europe, Diagnosis Population (millions), 2002–2016 57
Figure 42: Anti-Hypertensive Market, Top Five Countries in Europe, Prescription Population (millions), 2002–2016 58
Figure 43: Anti-Hypertensive Market, Japan, Sales Value ($bn), 2002–2016 59
Figure 44: Anti-Hypertensive Market, Japan, Annual Cost of Therapy ($), 2002–2016 60
Figure 45: Anti-Hypertensive Market, Japan, Treatment Usage Pattern (millions), 2002–2016 61
Figure 46: Anti-Hypertensive Market, Japan, Treatment-Seeking Population (millions), 2002–2016 62
Figure 47: Anti-Hypertensive Market, Japan, Diagnosed Population (millions), 2002–2016 63
Figure 48: Anti-Hypertensive Market, Japan, Prescription Population (millions), 2002–2016 64
Figure 49: Anti-Hypertensive Market, Global, R&D Pipeline by Indication (%), October 2010 65
Figure 50: Anti-Hypertensive Market, Global, R&D Pipeline by Phase in Hypertension Market (%), October 2010 71
Figure 51: Anti-Hypertensive Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market (%), October 2010 76
Figure 52: Anti-Hypertensive Market, Global, Market Share of Top Manufacturers (%), 2009 83
Figure 53: Anti-Hypertensive Market, Global, SWOT – Novartis, 2010 85
Figure 54: Anti-Hypertensive Market, Global, SWOT – Merck, 2010 86
Figure 55: Anti-Hypertensive Market, Global, SWOT – AstraZeneca, 2010 87
Figure 56: Anti-Hypertensive Market, Global, SWOT – United Therapeutics, 2010 88
Figure 57: Anti-Hypertensive Market, Global, SWOT – Actelion Ltd, 2010 90
Figure 58: Anti-Hypertensive Market, Global, SWOT – Pfizer, 2010 91
Figure 59: Anti-Hypertensive Market, Global, M&A Deals by Deal Type (%), 2010 92
Figure 60: Anti-Hypertensive Market, Global, Major Licensing Agreements By Indication (%), 2005–2010 94
Figure 61: Anti-Hypertensive Market, Global, Major Licensing Agreements By Phase (%), 2005–2010 95
Figure 62: Anti-Hypertensive Market, Global, Major Licensing Agreements By Geography (%), 2005–2010 95

“Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market” report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global antihypertensive market. The report analyzes the markets for antihypertensive disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Global Anti-Hypertensive Market is Set to Show Flat Growth in the near Future

In 2009, the global anti-hypertensive market was estimated to be worth $27.2 billion, representing a Compound Annual Growth Rate (CAGR) of 5.0% between 2002 and 2009. The market is forecast to reach $30 billion by 2016, indicating a CAGR of 1.5% between 2009 and 2016. The primary reason for slight and gradual growth in the market is the patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2007.

The global anti-hypertensive market is expected to witness a series of patent expiries between 2007 and 2015, which includes most of the top selling blockbuster drugs in the anti-hypertensive market. The major drugs that are set to lose patent protection include Novartis’s Diovan (2012), Sanofi Aventis’s Avapro (2012), Novartis’s Exforge (2012), Takeda/AstraZeneca’s Blopress/Atacand (2012), Pfizer’s Revatio (2012), Actelion’s Tracleer (2015), and United Therapeutics Remodulin (2014). All these drugs together accounted for more than $19.4 billion in revenues in 2009. Merck’s Cozaar patent expired in April 2010. The sales of Cozaar for the year 2009 were $3.6 billion. Pfizer’s Norvasc, which was once the world’s most prescribed drug for hypertension and angina, saw a sales decline of 12% in 2009 due to genericization in 2007. Thus, the series of upcoming patent expiries in the hypertension as well as PAH markets are set to lead to a decline in the market in the near future. However, due to increased usage of fixed dose-combinations and the entry of generics, the market is expected to rise slightly after 2015.

The current anti-hypertensive pipeline does offer some promising novel products, such as SPP635, Actos, LCZ696, QT1571, ACT-293987, PS-433540, Macitentan and Riociguat, indicated for the treatment of hypertension and PAH. However, the revenues generated from these products are not expected to completely make up for the revenue losses due to patent expiries. Thus, the overall global anti-hypertensive market is expected to show flat growth during the forecast period.